| Balance Sheets | 2026-03-31 | 2025-09-30 | 2025-06-30 | |
|---|---|---|---|---|
| Cash | 4,908,769 | 3,757,594 | 2,849,816 | |
| Prepaid expenses and other current assets | 466,330 | 407,946 | 457,556 | |
| Total current assets | 5,375,099 | 4,165,540 | 3,307,372 | |
| Property and equipment, net | 119,927 | 196,521 | 241,082 | |
| Intangible assets, net | NaN | NaN | 0 | |
| Deferred offering costs, non-current | 26,438 | NaN | NaN | |
| Total other assets | 146,365 | 196,521 | 241,082 | |
| Total assets | 5,521,464 | 4,362,061 | 3,548,454 | |
| Total mezzanine equity | NaN | 0 | 0 | |
| Due to related parties-Related Party | NaN | NaN | 99,875 | |
| Due to related parties | NaN | 0 | NaN | |
| Accounts payable | 280,315 | 683,707 | 1,040,967 | |
| Accrued expenses and other current liabilities | 180,361 | 222,178 | 222,843 | |
| Total current liabilities | 460,676 | 905,885 | 1,363,685 | |
| Common stock, 0.01 par value, 100,000,000 shares authorized, 1,887,535 and 1,061,533 shares issued and outstanding as of march 31, 2026 and december 31, 2025, respectively | 18,875 | 5,183 | 30,260 | |
| Additional paid-in capital | 122,108,934 | 116,684,259 | 113,506,692 | |
| Accumulated deficit | -116,479,965 | -112,652,321 | -110,778,652 | |
| Accumulated other comprehensive loss | -587,056 | -580,945 | -573,531 | |
| Total shareholders equity | 5,060,788 | 3,456,176 | 2,184,769 | |
| Total liabilities, mezzanine equity, and shareholders equity | 5,521,464 | 4,362,061 | 3,548,454 | |
Enveric Biosciences, Inc. (ENVB)
Enveric Biosciences, Inc. (ENVB)